Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KNSA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -143.62 Med: -3.95 Max: 433.94
Current: 53.09
During the past 10 years, the highest EV-to-EBITDA of Kiniksa Pharmaceuticals International was 433.94. The lowest was -143.62. And the median was -3.95.
KNSA's EV-to-EBITDA is ranked worse than 89.31% of 739
companies
in the Drug Manufacturers industry
Industry Median: 13.37
vs KNSA: 53.09
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Kiniksa Pharmaceuticals International (NAS:KNSA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kiniksa Pharmaceuticals International's PE Ratio (TTM) for today is calculated as:
Kiniksa Pharmaceuticals International's share price for today is $76.00.
Kiniksa Pharmaceuticals International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.970.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals International EV-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kiniksa Pharmaceuticals International EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Kiniksa Pharmaceuticals International's EV-to-EBITDA falls into.
Kiniksa Pharmaceuticals International's current Enterprise Value is $5,417.5 Mil.
Kiniksa Pharmaceuticals International's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $102.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals International (KNSA) has a EV-to-EBITDA of 53.09 as of Aug. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Kiniksa Pharmaceuticals International. According to the industry distribution chart, Kiniksa Pharmaceuticals International ranks #660 out of 739 companies in the Drug Manufacturers industry, placing it in the top 89.3%.
Is Kiniksa Pharmaceuticals International's EV-to-EBITDA too high?
Kiniksa Pharmaceuticals International's current EV-to-EBITDA is 53.09. The Drug Manufacturers industry median EV-to-EBITDA is 13.37. Kiniksa Pharmaceuticals International's value of 53.09 is 297.1% above this industry median. Based on the distribution chart, Kiniksa Pharmaceuticals International ranks #660 out of 739 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Kiniksa Pharmaceuticals International has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's EV-to-EBITDA compare to INDV and AMRX?
According to the Drug Manufacturers industry distribution chart, Kiniksa Pharmaceuticals International ranks #660 out of 739 companies for EV-to-EBITDA. This places Kiniksa Pharmaceuticals International in the lower half of its industry. The industry median EV-to-EBITDA is 13.37. Kiniksa Pharmaceuticals International's value of 53.09 is 297.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.37, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kiniksa Pharmaceuticals International's current EV-to-EBITDA of 53.09 is 297.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Kiniksa Pharmaceuticals International. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kiniksa Pharmaceuticals International's current EV-to-EBITDA is 53.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International (KNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is $53.86, compared to a current price of $76.00 — trading 41.1% above its estimated fair value. The current EV-to-EBITDA is 53.09 and 297.1% above the Drug Manufacturers industry median of 13.37. Kiniksa Pharmaceuticals International's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (KNSA), the current EV-to-EBITDA is 53.09 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued.
The current stock price of $76.00 is trading 41.1% above its estimated GF Value™ of $53.86.
GuruFocus considers Kiniksa Pharmaceuticals International to be Significantly Overvalued.
Key valuation signals for KNSA:
EV-to-EBITDA: 53.09
GF Value™: $53.86 vs. price of $76.00 (41.1% above fair value)
Industry Position: 297.1% above the Drug Manufacturers median (#660 of 739)
No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
50GF Score
Get the complete analysis for KNSA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNSA has been successfully added to your 
